Could the same medication that causes people to lose weight hold the key to reducing drinking? In a new paper at the European ...

GLP-1 drugs achieve some of these effects by directly affecting the brain’s cravings for food, and that might also extend to ...

New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in ...

Drugs like Ozempic — which mimic the appetite-suppressing GLP-1 hormone the body naturally produces after eating — have been ...

To investigate whether Liraglutide had a neuroprotective after cardiac arrest and return of spontaneous circulation (CA/ROSC) and explore its potential mechanisms. Adopting an 8-min asphyxial cardiac ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

New research presented at the European Congress on Obesity (ECO 2025) and published in the journal Diabetes, Obesity and ...

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...

Learn how GLP-1 receptor agonists show promise in reducing alcohol consumption and aiding weight loss in obesity treatment.

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and ...